These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34947940)

  • 1. Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease.
    Nijakowski K; Rutkowski R; Eder P; Korybalska K; Witowski J; Surdacka A
    Life (Basel); 2021 Dec; 11(12):. PubMed ID: 34947940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Salivary Markers for Differential Diagnosis of Crohn's Disease and Ulcerative Colitis.
    Nijakowski K; Rutkowski R; Eder P; Simon M; Korybalska K; Witowski J; Surdacka A
    Life (Basel); 2021 Sep; 11(9):. PubMed ID: 34575091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy.
    Lowe SC; Sauk JS; Limketkai BN; Kwaan MR
    J Gastrointest Surg; 2021 Jan; 25(1):211-219. PubMed ID: 33140318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of soluble immunoglobulins A and G and their coated bacteria in feces of patients with inflammatory bowel disease.
    Lin R; Chen H; Shu W; Sun M; Fang L; Shi Y; Pang Z; Wu W; Liu Z
    J Transl Med; 2018 Dec; 16(1):359. PubMed ID: 30558634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting.
    Bokemeyer B; Ghiani M; Fuchs A; Deiters B; Hardtstock F; Brandes A; Knop J; Orzechowski HD; Wilke T
    Int J Colorectal Dis; 2020 Aug; 35(8):1587-1598. PubMed ID: 32424526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.
    Sassaki LY; Miszputen SJ; Kaiser Junior RL; Catapani WR; Bafutto M; Scotton AS; Zaltman C; Baima JP; Ramos HS; Faria MAG; Gonçalves CD; Guimaraes IM; Flores C; Amarante HMBS; Nones RB; Parente JML; Lima MM; Chebli JM; Ferrari MLA; Campos JF; Sanna MGP; Ramos O; Parra RS; da Rocha JJR; Feres O; Feitosa MR; Caratin RF; Senra JT; Santana GO
    World J Gastroenterol; 2021 Jun; 27(23):3396-3412. PubMed ID: 34163120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and salivary IgA antibody responses to Saccharomyces cerevisiae, Candida albicans and Streptococcus mutans in orofacial granulomatosis and Crohn's disease.
    Savage NW; Barnard K; Shirlaw PJ; Rahman D; Mistry M; Escudier MP; Sanderson JD; Challacombe SJ
    Clin Exp Immunol; 2004 Mar; 135(3):483-9. PubMed ID: 15008983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
    Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
    World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
    [No Abstract]   [Full Text] [Related]  

  • 12. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.
    Alulis S; Vadstrup K; Olsen J; Jørgensen TR; Qvist N; Munkholm P; Borsi A
    BMC Health Serv Res; 2021 Aug; 21(1):836. PubMed ID: 34407821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations.
    Le Berre C; Loy L; Lönnfors S; Avedano L; Piovani D
    World J Gastroenterol; 2020 Aug; 26(29):4343-4355. PubMed ID: 32848338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA signatures differentiate Crohn's disease from ulcerative colitis.
    Schaefer JS; Attumi T; Opekun AR; Abraham B; Hou J; Shelby H; Graham DY; Streckfus C; Klein JR
    BMC Immunol; 2015 Feb; 16():5. PubMed ID: 25886994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
    Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
    World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary Stress/Immunological Markers in Crohn's Disease and Ulcerative Colitis.
    Finamore A; Peluso I; Cauli O
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
    Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
    World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficiency of N-acetylgalactosamine in O-linked oligosaccharides of IgA is a novel biologic marker for Crohn's disease.
    Inoue T; Iijima H; Tajiri M; Shinzaki S; Shiraishi E; Hiyama S; Mukai A; Nakajima S; Iwatani H; Nishida T; Mizushima T; Yasui T; Isaka Y; Kanto T; Tsujii M; Miyoshi E; Wada Y; Takehara T
    Inflamm Bowel Dis; 2012 Sep; 18(9):1723-34. PubMed ID: 22241690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
    Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
    Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.